United Therapeutics Corporation
United Therapeutics Corporation/ US91307C1027 /
UTHR
|
2024-07-26 10:00:00 PM
|
Chg.
+1.8500
|
Volume |
Bid10:31:29 PM |
Ask10:31:29 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
338.2200USD
|
+0.55%
|
290,257
Turnover: 51.6 mill. |
325.7200Bid Size: 100 |
344.0000Ask Size: 200 |
15 bill.USD |
- |
16.08 |
Business description
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.
Management board & Supervisory board
| CEO |
| Dr. Martine A. Rothblatt |
| Management board |
| James C. Edgemond, Michael Benkowitz, Paul A. Mahon |
| Supervisory board |
| Dr. Martine A. Rothblatt, Christopher Causey, Christopher Patusky, Dr. Judy D. Olian, Linda Maxwell, M.D., Louis Sullivan, Nilda Mesa, Prof. Raymond Dwek, Ray Kurzweil, Richard Giltner, Tommy G. Thompson, Jan Malcolm |
Company data
| Name: |
United Therapeutics Corporation |
| Address: |
1000 Spring Street,Silver Spring, Maryland 20910, USA |
| Phone: |
+1-301-608-9292 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.unither.com/index |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
12-31 |
| Free Float: |
- |
| IPO date: |
1999-06-17 |
Investor relations
| Name: |
- |
| IR phone: |
+1-301-608-9292 |
| IR Fax: |
- |
| IR e-mail: |
-
|
Main Shareholders
| Freefloat |
|
61.80% |
| BlackRock, Inc |
|
9.60% |
| The Vanguard Group |
|
8.90% |
| Renaissance Technologies LLC |
|
8.10% |
| Avoro Capital Advisors LLC |
|
6.40% |
| FMR, LLC |
|
5.20% |
